This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 May;30(3):303-7.

doi: 10.1016/j.ctrv.2004.01.008.

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer

Hetty Carraway¹, Antonio C Wolff

Affiliations

PMID: 15059653
DOI: 10.1016/j.ctrv.2004.01.008

Comment

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer

Hetty Carraway et al. Cancer Treat Rev. 2004 May.

. 2004 May;30(3):303-7.

doi: 10.1016/j.ctrv.2004.01.008.

Authors

Hetty Carraway¹, Antonio C Wolff

Affiliation

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 186, Baltimore, MD 21231-1000, USA.

PMID: 15059653
DOI: 10.1016/j.ctrv.2004.01.008

No abstract available

PubMed Disclaimer

Comment on

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Baum M, et al. Cancer. 2003 Nov 1;98(9):1802-10. doi: 10.1002/cncr.11745. Cancer. 2003. PMID: 14584060 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science